A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours

Objective To evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumour activity of AMG 404, a fully human IgG1 monoclonal antibody targeting programmed cell death-1, in patients with advanced solid tumours.Design First-in-human phase I study comprising eight dose expansion...

Descrición completa

Detalles Bibliográficos

Principais autores:	Yasutoshi Kuboki, Hendrik-Tobias Arkenau, Vivek Subbiah, Timothy Price, Gerald Falchook, Hans Prenen, Rafal Dziadziuszko, Hansen Wong, Iwona Lugowska, Daniel Tan, Weibing Shi, Ryota Shibaki, Min Hee Hong, Sant P Chawla, Jose G Monzon, Mun Hui, Caio Max Rocha Lima, Kejia Wang, Antreas Hindoyan, Mira Kistler
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMJ Publishing Group 2025-05-01
Series:	BMJ Open
Acceso en liña:	https://bmjopen.bmj.com/content/15/5/e088578.full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!